Purification and characterisation of soluble intercellular adhesion molecule-1 (sICAM-1) and its effect on cell-mediated cytolysis of tumour cells

International Journal of Oncology

Volumn 10, Issue 4, 1997, Pages 827-834

  Young, Douglas Garrie ^a   Jackson, Andrew Mark ^a,b   James, Keith ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Bladder cancer; Immunoaffinity chromatography; Soluble intercellular adhesion molecule 1; Western blotting

Indexed keywords

BCG VACCINE; INTERCELLULAR ADHESION MOLECULE 1;

ARTICLE; BLADDER CANCER; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0030895843     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.10.4.827     Document Type: Article

References (18)

1. Marlin SD and Springer TA: Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell 51: 813-819, 1987.
2. Dougherty GJ, Murdoch S and Hogg N: The function of human intercellular adhesion molecule-1 (ICAM-1) in the generation of an immune response. Eur J Immunol 18: 35-39, 1988.
3. Makgoba MW, Sanders ME, Ginther Luce GE, Gugel EA, Dustin ML, Springer TA and Shaw S: Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity. Eur J Immunol 18: 637-640, 1988.
4. Clayberger C, Medeiros LJ, Link MP, Warnke RA, Wright A, Koller TD, Smith SD and Krensky AM: Absence of cell surface LFA-1 as a mechanism of escape from immunosurveillance. Lancet ii: 533-536, 1987.
5. Rothlein R, Mainolfi EA, Czajkowski M and Marlin SD: A form of circulating ICAM-1 in human serum. J Immunol 147: 3788-3793, 1991.
6. Seth R, Raymond FD and Makgoba MW: Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders. Lancet 338: 83-84, 1991.
7. Gearing AJH and Newman W: Circulating adhesion molecules in disease. Immunol Today 14: 506-512, 1993.
8. Marlin SD, Staunton DE, Springer TA, Stratowa C, Sommergruber W and Merluzzi VJ: A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. Nature 344: 70-72, 1990.
9. Becker JC, Dummer R, Hartmann AA, Burg G and Schmidt RE: Shedding of ICAM-1 from human melanoma cell lines induced by IFNγ and tumor necrosis factor-α: functional consequences on cell-mediated cytotoxicity. J Immunol 147: 4398-4401, 1991.
10. Becker JC, Termeer C, Schmidt RE and Bröcker E-B: Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol 151: 7224-7232, 1993.
11. Rieckmann P, Michel U, Albrecht M, Brück W, Wöckel L and Felgenhauer K: Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells. J Neuroimmunol 60: 9-15, 1995.
12. Staunton DE, Ockenhouse CF and Springer TA: Soluble intercellular adhesion molecule 1-immunoglobulin G1 immunoadhesin mediates phagocytosis of malaria-infected erythrocytes. J Exp Med 176: 1471-1476, 1992.
13. Welder CA, Lee DHS and Takei F: Inhibition of cell adhesion by microspheres coated with recombinant soluble intercellular adhesion molecule-1. J Immunol 150: 2203-2210, 1993.
14. Meyer DM, Dustin ML and Carron CP: Characterization of intercellular adhesion molecule-1 ectodomain (sICAM-1) as an inhibitor of lymphocyte function-associated molecule-1 interaction with ICAM-1. J Immunol 155: 3578-3584, 1995.
15. Jackson AM, Alexandrov AB, Gribben SC, Esuvarnathan K and James K: Expression and shedding of ICAM-1 in bladder cancer and its immunotherapy. Int J Cancer 55: 921-925, 1993.
16. Jackson AM, Alexandroff AB, Kelly RW, Skibinska A, Esuvaranathan K, Prescott S, Chisholm GD and James K: Changes in urinary cytokines and soluble intercellular adhesion moleculc-l (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy. Clin Exp Immunol 99: 369-375, 1995.
17. Lamm DL: Carcinoma in situ. Urol Clin North Am 19: 499-508, 1992.
18. Prescott S, James K, Busuttil A, Hargreave TB, Chisholm GD and Smyth JF: HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br J Urol 63: 264-269, 1989.